Key facts
- This page summarizes Mark W. Hahn's Form 4 filing for Verona Pharma plc (VRNA).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 01 May 2025, 20:55.
Mark W. Hahn - 07 Aug 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- VRNA
- Reported as of
- 07 Aug 2024
- Net transaction value
- -$811,433
- SEC form
- 4
- Accepted by SEC
- 01 May 2025, 20:55:34 UTC
- Prior SEC filing
- 05 Aug 2024
- Next SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Fisher, Attorney-in-fact for Mark Hahn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark W. Hahn filed Form 4 for Verona Pharma plc (VRNA) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 05 Aug 2024.
- Current net transaction value: -$811,433.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $0
- Shares
- +229,512
- Change %
- +1.7%
- Price
- $0.000000
- Shares after
- 13,556,360
- Date
- 29 Apr 2025
- Ownership
- Direct
- Footnotes
- F1
VRNA
transaction
Ordinary Shares
Sale
- Transaction value
- $811,433
- Shares
- -90,360
- Change %
- -0.67%
- Price
- $8.98
- Shares after
- 13,466,000
- Date
- 29 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRNA
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +1,200,000
- Change %
- Price
- $0.000000
- Shares after
- 1,200,000
- Date
- 07 Aug 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,200,000
- Exercise price
- Footnotes
- F1, F5, F6
VRNA
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +675,000
- Change %
- Price
- $0.000000
- Shares after
- 675,000
- Date
- 29 Apr 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 675,040
- Exercise price
- Footnotes
- F1, F5, F6
VRNA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -229,512
- Change %
- -34%
- Price
- $0.000000
- Shares after
- 445,488
- Date
- 29 Apr 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 229,512
- Exercise price
- Footnotes
- F1, F5, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Footnote F2
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on May 24, 2022 solely with the intent to cover taxes in connection with the vesting of Restricted Share Units.
Footnote F3
The price reported represents the sale price of the ADSs divided by eight (8).
Footnote F4
Consists of (i) 2,725,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 340,625 ADSs); and (ii) 10,741,000 Ordinary Shares underlying 1,342,625 ADSs.
Footnote F5
Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
Footnote F6
The RSUs were earned upon the satisfaction of the performance condition in connection with the Issuer's first commercial sale of ensifentrine. Following the satisfaction of the performance condition, the RSUs vest in equal quarterly installments on each of May 1, 2025, August 1, 2025, November 1, 2025, February 1, 2026, May 1, 2026 and August 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F7
The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q1 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of August 1, November 1, February 1 and May 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.